Menu
Search
|

Menu

Close
X

Curis Inc CRIS.OQ (NASDAQ Stock Exchange Global Market)

0.50 USD
-- (--)
As of Feb 22
chart
Previous Close 0.50
Open --
Volume --
3m Avg Volume 297,783
Today’s High --
Today’s Low --
52 Week High 3.22
52 Week Low 0.49
Shares Outstanding (mil) 163.98
Market Capitalization (mil) 81.61
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.50 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY17
7
FY16
8
FY15
8
EPS (USD)
FY17
-0.314
FY16
-0.456
FY15
-0.506
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.75
Price to Sales (TTM)
vs sector
9.07
8.23
Price to Book (MRQ)
vs sector
2.68
5.26
Price to Cash Flow (TTM)
vs sector
--
26.16
Total Debt to Equity (MRQ)
vs sector
140.82
15.44
LT Debt to Equity (MRQ)
vs sector
124.01
12.05
Return on Investment (TTM)
vs sector
-92.89
13.63
Return on Equity (TTM)
vs sector
-165.77
15.25

EXECUTIVE LEADERSHIP

James McNab
Independent Chairman of the Board, Since 2002
Salary: --
Bonus: --
Ali Fattaey
President, Chief Executive Officer, Director, Since 2014
Salary: $527,677.00
Bonus: --
James Dentzer
Chief Financial Officer, Chief Administrative Officer, Since 2016
Salary: $320,846.00
Bonus: --
David Tuck
Chief Medical Officer, Since 2016
Salary: $371,308.00
Bonus: --
Lori Kunkel
Director, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

4 Maguire Rd
LEXINGTON   MA   02421-3112

Phone: +1617.5036500

Curis, Inc. is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company's drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target programmed death ligand-1 (PDL1) and V-domain Ig suppressor of T-cell activation (VISTA) immune checkpoint proteins, both of which independently function as negative regulators of immune activation. CA-4948 is an oral small molecule drug candidate that is designed to inhibit the Interleukin-1 receptor-associated kinase 4 (IRAK4) kinase, which is a transducer of toll-like receptor or certain interleukin receptor signaling pathways.

SPONSORED STORIES